Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Sanara MedTech Inc. is a U.S.-based medical technology company focused on advanced wound care and surgical site infection prevention solutions. The company operates within the medical devices and healthcare products industries, primarily serving hospitals, outpatient surgical centers, and wound care clinics. Its core offerings include biologic, antimicrobial, and tissue-based products designed to improve patient outcomes and reduce complications associated with chronic wounds and surgical procedures.
The company generates revenue mainly through the sale of proprietary wound care dressings and surgical products marketed under clinically focused brands. Sanara’s strategic positioning emphasizes evidence-based products, clinician education, and hospital integration, differentiating it from commoditized wound care suppliers. Sanara MedTech traces its roots to Hydrofera, LLC, a wound care company founded in the early 2000s, and adopted its current name in 2022 to reflect a broader medtech strategy and expanded surgical focus.
Business Operations
Sanara MedTech operates through two primary business segments: Sanara Wound Care and Sanara Surgical. Sanara Wound Care focuses on advanced wound dressings and biologic products used in the management of chronic and complex wounds, while Sanara Surgical targets products designed to reduce surgical site infections and support post-operative healing. Revenue is generated through direct sales to healthcare providers and distribution partners.
Operations are predominantly U.S.-based, with sales concentrated in domestic healthcare systems. The company controls proprietary product technologies, clinical data, and branded platforms developed internally or through acquired assets. Sanara conducts its operations through wholly owned subsidiaries, including Sanara Wound Care, Inc. and Sanara Surgical, LLC, which house product development, commercialization, and sales activities.
Strategic Position & Investments
Sanara MedTech’s strategy centers on expanding its footprint in surgical and advanced wound care markets through targeted acquisitions, product line extensions, and clinical evidence generation. A key growth initiative has been the expansion of its surgical portfolio to complement its legacy wound care offerings, allowing cross-selling within hospital systems and outpatient settings.
The company has completed selective acquisitions of wound care and biologic assets to strengthen its technology base and intellectual property portfolio. Notably, Sanara acquired advanced wound care product assets from Cook Biotech to broaden its biologics platform. The company continues to invest in emerging wound healing technologies and infection prevention solutions, though details on early-stage or pipeline technologies are limited in public disclosures.
Geographic Footprint
Sanara MedTech is headquartered in the United States, with its primary corporate offices and operational footprint located domestically. The company’s commercial activities are largely concentrated across North America, where it maintains relationships with hospitals, surgery centers, and wound care providers.
While Sanara’s products may be used internationally through distribution arrangements, publicly available information indicates that the company’s direct operational and revenue exposure outside the U.S. remains limited. Data on material international investments or manufacturing operations is inconclusive based on available public sources.
Leadership & Governance
Sanara MedTech is led by an executive team with experience in medical devices, wound care, and healthcare commercialization. The leadership emphasizes disciplined growth, clinical validation, and alignment with healthcare providers to drive adoption of its products.
Key executives disclosed in public filings include:
- Brian D. Ellett – President and Chief Executive Officer
- David McClellan – Chief Financial Officer
Information regarding additional executive officers and founders is limited or inconsistently reported across public sources; data inconclusive based on available public sources.